As PD-1 and PD-L1 are associated as a receptor-ligand pair, with T cells expressing PD-1 and tumor cells expressing PD-L1, anti-PD-L1 immunotherapy has also been shown to be similarly dependent on the gut microbiome. This evidence concerns the gene CD274 and neoplasm.